Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Genitourinary 3Gastrointestinal 3Dermatologic 3Thoracic 2Gynecologic 2Lymphoid 1Breast 1

Conditions

Hodgkin Disease 47Lymphoma 22Lymphoma, Non-Hodgkin 18Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 12Melanoma 9Lymphoma, B-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Lymphoma, Follicular 7Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Carcinoma, Renal Cell 5Burkitt Lymphoma 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, B-Cell, Marginal Zone 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3

Interventions

pembrolizumab 2fludarabine 1epacadostat 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1Carboxylesterase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × Nivolumab × Lymphoid × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡